# A Study to Evaluate the Effect of Two Fixed-Dose Leucine, Sildenafil and Metformin Combinations on Blood Pressure in Individuals With Hypertension

Study · id `cardio:ct-nct07647003` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07647003](<https://clinicaltrials.gov/study/NCT07647003>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07647003

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT07647003. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-15 (anticipated); primary completion 2027-05-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT07647003, source copy `cardio:ctgov-nct07647003-2026-06-15`, retrieved 2026-10-26)
- Planned start: 2026-10-15 (anticipated) (ClinicalTrials.gov record NCT07647003, source copy `cardio:ctgov-nct07647003-2026-06-15`, retrieved 2026-10-26)
- Primary completion: 2027-05-02 (anticipated) (ClinicalTrials.gov record NCT07647003, source copy `cardio:ctgov-nct07647003-2026-06-15`, retrieved 2026-10-26)
- Completion: 2027-07-07 (anticipated) (ClinicalTrials.gov record NCT07647003, source copy `cardio:ctgov-nct07647003-2026-06-15`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07647003-2026-06-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Effect of Two Fixed-Dose Leucine, Sildenafil and Metformin Combinations on Blood Pressure in Individuals With Hypertension
- Acronym: NS-HTN-01
- Condition: Hypertension
- Intervention (Drug): NS-0200 (low sildenafil)
- Intervention (Drug): NS-0200 (higher sildenafil)
- Intervention (Other): Placebo
- Lead sponsor: NuSirt Biopharma
- Lead sponsor class: INDUSTRY
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 638b08f2c0a4ca54d014a17676b2307564344eb5669a6ae87a624cade247c263
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
